Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
US8680152B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 2, 2012 |
| Grant date | Mar 25, 2014 |
| Priority date | — |
| Expiry date | May 2, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.